Benzinga | May 27, 2021 08:47AM EDT

Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany

* Dynavax Technologies Corporation (NASDAQ:DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021.

* Financial terms were not disclosed.

* In February, the European Commission granted marketing authorization for HEPLISAV B.

* The vaccine combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist CpG 1018 adjuvant to enhance the immune response.

* Price Action: DVAX shares are up 1.9% at $8.01 during the premarket session on the last check Thursday.